Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Non Operating Income (2023 - 2025)

Compass Therapeutics' Non Operating Income history spans 3 years, with the latest figure at $2.3 million for Q4 2025.

  • For Q4 2025, Non Operating Income rose 47.57% year-over-year to $2.3 million; the TTM value through Dec 2025 reached $6.4 million, down 12.43%, while the annual FY2025 figure was $6.4 million, 12.41% down from the prior year.
  • Non Operating Income for Q4 2025 was $2.3 million at Compass Therapeutics, up from $1.6 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $2.3 million in Q4 2025 and bottomed at $1.2 million in Q2 2025.
  • The 3-year median for Non Operating Income is $1.9 million (2023), against an average of $1.8 million.
  • The largest YoY upside for Non Operating Income was 47.57% in 2025 against a maximum downside of 39.82% in 2025.
  • A 3-year view of Non Operating Income shows it stood at $2.0 million in 2023, then dropped by 21.94% to $1.5 million in 2024, then skyrocketed by 47.57% to $2.3 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Non Operating Income are $2.3 million (Q4 2025), $1.6 million (Q3 2025), and $1.2 million (Q2 2025).